Reactivate a gene to treat Rett syndrome
MeCP2 reactivation from the inactive X chromosome as treatment for Rett syndrome
This study is exploring a new way to help girls with Rett syndrome by trying to turn on a gene that’s important for brain function, using a special method to deliver it to the brain cells that need it, with hopes of improving their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10930116 on NIH RePORTER |
What this research studies
This research investigates a potential treatment for Rett syndrome, a severe neurodevelopmental disorder primarily affecting girls. The approach focuses on reactivating the inactive X chromosome to restore the function of the MECP2 gene, which is crucial for normal brain function. By using a viral delivery method, the study aims to introduce the functional gene into neurons that currently lack it, potentially reversing the symptoms of the disorder. The research utilizes animal models that closely mimic human symptoms to evaluate the effectiveness of this gene therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are females diagnosed with Rett syndrome who have mutations in the MECP2 gene.
Not a fit: Patients with Rett syndrome who do not have MECP2 mutations or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option for individuals with Rett syndrome, potentially improving their neurological function and quality of life.
How similar studies have performed: Previous research has shown promising results in reversing Rett syndrome symptoms in animal models using similar gene therapy approaches, indicating potential for success in this study.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Liu, X. Shawn — Columbia University Health Sciences
- Study coordinator: Liu, X. Shawn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.